Medicine benefits remain one of the clearest ways members feel the value of their medical scheme, according to the 2025 Mediscor Medicines Review. The report describes not runaway growth but steady pressure from utilisation, high-cost therapies, chronic disease and member affordability. The analysis draws on fee-for-service schemes with ongoing Mediscor PBM contracts, covering more than 1 million beneficiaries. Year-on-year shifts,…
Tag: Medicine Expenditure
-
Mediscor Medicines Review 2024: Key Insights Revealed
The Mediscor Medicines Review 2024 reveals a significant 5.0% increase in medicine expenditure. This marks the most substantial rise in the past three years, presenting a complex challenge for South Africa’s healthcare sector. As a leading pharmaceutical benefits management (PBM) organisation covering over 2.6 million lives, Mediscor’s annual analysis provides a critical barometer for the industry. The 2024 report highlights…